Harbin Pharmaceutical Group (600664.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 600 million yuan, a year-on-year increase of 82.66%.

Zhitong Finance APP News, Harbin Pharmaceutical Group (600664.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 12.352 billion yuan, a year-on-year increase of 2.75%; net profit attributable to the parent company was 600 million yuan, a year-on-year increase of 82.66%; net profit after deducting non-recurring gains and losses was 529 million yuan, a year-on-year increase of 83.18%; basic earnings per share were 0.24 yuan.